Download Yuko - Genomic

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
Genomic Health, Inc.
Yuko Soneoka, Ph.D., J.D.
Senior Corporate Counsel, IP
Director of Intellectual Property
January 31, 2013
What We Do
• Genomic Health is a global personalized genomics health
company focusing on cancer
• Conduct studies to understand which patterns of gene
expression within a tumor are linked to a response to cancer
therapy or to the likelihood that the cancer will return or
metastasize
• Develop clinically validated tests that provide the genomic
profile of an individual’s tumor in the form of a “score” that
helps individualize cancer treatment planning
2
Leading a Revolution in Cancer Care
Do I need
chemotherapy?
Do I have an
aggressive
disease?
Do I need
radiation?
Do I need
surgery?
Invasive
Breast Cancer
Stage II/ MMR
Colon Cancer
DCIS
Breast Cancer
Prostate
Cancer
2005
2006
2007
2008
2009
2010
NGS Research
3
* Estimated
2011
2012
Do I need
Oxaliplatin?
Stage II/III
Colon Cancer
2013*
NGS Development
2014*
DCIS Breast Cancer Assay
DCIS Score Identifies
75% of Patients with
Lower Risk Disease
Who May Avoid
Radiation Treatment
“One of the year’s leading
medical breakthroughs…”
4
Delivering Better Outcomes in Cancer
Cancer’s Toll in 2012
•1.6 million new cancers will be diagnosed
in the U.S.1
•~577,000 patients will die from their disease1
•80 billion dollars will be spent on cancer
therapies with an average efficacy of 25%2
•60 billion dollars will be wasted
In Early Stage ER+ Invasive
Breast Cancer
•>100,000 patients will be diagnosed in the U.S.
•>50% percent will receive chemotherapy3
•<4% of N- patients will benefit from chemotherapy
The Oncotype DX® Value Proposition
•Demonstrated 37% change in early-stage
breast cancer treatment decisions
•Hundreds of millions of dollars in
healthcare savings
•>320,000 patients tested
5
1 ACS 2012; 2 Burrill 2009; 3 Company estimates
Thank You
6